Symbols / EDSA $5.82 -5.21% Edesa Biotech, Inc.
EDSA Chart
About
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07, a monoclonal antibody, which is in a Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, a human monoclonal antibody candidate that binds to chemokine ligand 10 (CXCL10) and inhibits the interaction of CXCL10 with its receptors, CXCR3A, and CXCR3B. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 48.59M |
| Enterprise Value | 48.50M | Income | -7.82M | Sales | — |
| Book/sh | 0.56 | Cash/sh | 1.44 | Dividend Yield | — |
| Payout | 0.00% | Employees | 17 | IPO | — |
| P/E | — | Forward P/E | -3.02 | PEG | — |
| P/S | — | P/B | 10.41 | P/C | — |
| EV/EBITDA | -5.88 | EV/Sales | — | Quick Ratio | 16.51 |
| Current Ratio | 16.82 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -1.07 | EPS next Y | -1.93 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-02-13 16:00 | ROA | -55.33% |
| ROE | -96.39% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 8.35M |
| Shs Float | 3.16M | Short Float | 8.22% | Short Ratio | 0.05 |
| Short Interest | — | 52W High | 9.37 | 52W Low | 0.72 |
| Beta | -0.68 | Avg Volume | 4.44M | Volume | 181.81K |
| Target Price | $11.00 | Recom | Strong_buy | Prev Close | $6.14 |
| Price | $5.82 | Change | -5.21% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-03 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-03-13 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
- If You Invested $1,000 in Edesa Biotech Inc (EDSA) - Stock Titan Sun, 22 Mar 2026 03
- Edesa Biotech Inc. (EDSA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade Fri, 03 Apr 2026 00
- Edesa Biotech (NASDAQ:EDSA) Rating Increased to Hold at Wall Street Zen - MarketBeat Sun, 05 Apr 2026 05
- Why Did EDSA Stock Rally More Than 70% Today? - Stocktwits ue, 24 Feb 2026 20
- $EDSA stock is down 9% today. Here's what we see in our data. - Quiver Quantitative hu, 19 Mar 2026 07
- Market Movers | Winners: MOBX, BATL, EDSA | Losers: WORX, AGIG, PSIX - Trefis ue, 03 Mar 2026 08
- EDSA Stock Fund Price and Chart — HAM:EDSA - TradingView Fri, 27 Mar 2026 23
- Edesa Biotech stock surges on positive Phase 3 trial data - Investing.com ue, 24 Feb 2026 08
- Favourable Signals For Edesa Biotech: Numerous Insiders Acquired Stock - simplywall.st Fri, 31 Oct 2025 07
- Edesa Biotech (NASDAQ: EDSA) 2026 proxy seeks equity plan boost and director votes - Stock Titan Fri, 03 Apr 2026 20
- $EDSA stock is up 28% today. Here's what we see in our data. | EDSA Stock News - Quiver Quantitative ue, 03 Mar 2026 08
- Edesa Biotech (NASDAQ: EDSA) CEO adds 50,571 shares in open-market buys - Stock Titan Mon, 02 Mar 2026 08
- Edesa drug cuts death risk to 24% in Phase 3 ARDS trial - Stock Titan ue, 24 Feb 2026 08
- Insider Purchase: Chief Executive Officer of $EDSA Buys 10,000 Shares | EDSA Stock News - Quiver Quantitative Wed, 04 Mar 2026 08
- Vitiligo drug study moves ahead as Edesa picks trial manager - Stock Titan hu, 26 Mar 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Cost Of Revenue |
|
—
|
—
|
—
|
—
|
| Reconciled Cost Of Revenue |
|
—
|
—
|
—
|
—
|
| Gross Profit |
|
—
|
—
|
—
|
—
|
| Operating Expense |
|
7.13
+12.84%
|
6.32
-26.91%
|
8.64
-50.87%
|
17.59
|
| Research And Development |
|
3.67
+27.30%
|
2.88
-39.89%
|
4.79
-64.05%
|
13.34
|
| Selling General And Administration |
|
4.24
+2.66%
|
4.13
-6.67%
|
4.43
-12.06%
|
5.04
|
| General And Administrative Expense |
|
4.24
+2.66%
|
4.13
-6.67%
|
4.43
-12.06%
|
5.04
|
| Other Gand A |
|
4.24
+2.66%
|
4.13
-6.67%
|
4.43
-12.06%
|
5.04
|
| Other Operating Expenses |
|
-0.78
-12.26%
|
-0.70
-20.18%
|
-0.58
+25.53%
|
-0.78
|
| Total Expenses |
|
7.13
+12.84%
|
6.32
-26.91%
|
8.64
-50.87%
|
17.59
|
| Operating Income |
|
-7.13
-12.84%
|
-6.32
+26.91%
|
-8.64
+50.87%
|
-17.59
|
| Total Operating Income As Reported |
|
-7.91
-12.78%
|
-7.01
+23.94%
|
-9.22
+49.80%
|
-18.37
|
| EBITDA |
|
-7.01
-14.32%
|
-6.13
+27.52%
|
-8.46
+51.59%
|
-17.47
|
| Normalized EBITDA |
|
-6.95
-13.74%
|
-6.11
+27.58%
|
-8.44
+51.66%
|
-17.45
|
| Reconciled Depreciation |
|
0.12
-35.89%
|
0.19
+1.41%
|
0.18
+55.24%
|
0.12
|
| EBIT |
|
-7.13
-12.84%
|
-6.32
+26.91%
|
-8.64
+50.87%
|
-17.59
|
| Total Unusual Items |
|
-0.06
-183.29%
|
-0.02
+3.22%
|
-0.02
-2.97%
|
-0.02
|
| Total Unusual Items Excluding Goodwill |
|
-0.06
-183.29%
|
-0.02
+3.22%
|
-0.02
-2.97%
|
-0.02
|
| Net Income |
|
-7.19
-16.46%
|
-6.17
+26.32%
|
-8.37
+52.28%
|
-17.55
|
| Pretax Income |
|
-7.18
-16.46%
|
-6.17
+26.33%
|
-8.37
+52.28%
|
-17.55
|
| Net Non Operating Interest Income Expense |
|
0.00
-98.33%
|
0.15
-47.04%
|
0.29
+356.29%
|
0.06
|
| Net Interest Income |
|
0.00
-98.33%
|
0.15
-47.04%
|
0.29
+356.29%
|
0.06
|
| Interest Income Non Operating |
|
0.00
-98.33%
|
0.15
-47.04%
|
0.29
+356.29%
|
0.06
|
| Interest Income |
|
0.00
-98.33%
|
0.15
-47.04%
|
0.29
+356.29%
|
0.06
|
| Other Income Expense |
|
-0.06
-849.79%
|
-0.01
+71.13%
|
-0.02
-2.97%
|
-0.02
|
| Other Non Operating Income Expenses |
|
—
|
0.01
|
—
|
—
|
| Gain On Sale Of Security |
|
-0.06
-183.29%
|
-0.02
+3.22%
|
-0.02
-2.97%
|
-0.02
|
| Tax Provision |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
-62.50%
|
0.00
+52.61%
|
0.00
|
| Tax Effect Of Unusual Items |
|
-0.01
-183.29%
|
-0.00
+63.71%
|
-0.01
-57.15%
|
-0.01
|
| Net Income Including Noncontrolling Interests |
|
-7.19
-16.46%
|
-6.17
+26.32%
|
-8.37
+52.28%
|
-17.55
|
| Net Income From Continuing Operation Net Minority Interest |
|
-7.19
-16.46%
|
-6.17
+26.32%
|
-8.37
+52.28%
|
-17.55
|
| Net Income From Continuing And Discontinued Operation |
|
-7.19
-16.46%
|
-6.17
+26.32%
|
-8.37
+52.28%
|
-17.55
|
| Net Income Continuous Operations |
|
-7.19
-16.46%
|
-6.17
+26.32%
|
-8.37
+52.28%
|
-17.55
|
| Normalized Income |
|
-7.13
-15.97%
|
-6.15
+26.42%
|
-8.36
+52.31%
|
-17.53
|
| Net Income Common Stockholders |
|
-7.19
-16.46%
|
-6.17
+26.32%
|
-8.37
+52.28%
|
-17.55
|
| Diluted EPS |
|
-1.27
+34.20%
|
-1.93
+34.13%
|
-2.93
+60.14%
|
-7.35
|
| Basic EPS |
|
-1.27
+34.20%
|
-1.93
+34.13%
|
-2.93
+60.14%
|
-7.35
|
| Basic Average Shares |
|
5.68
+77.54%
|
3.20
+11.84%
|
2.86
+20.11%
|
2.38
|
| Diluted Average Shares |
|
5.68
+77.54%
|
3.20
+11.84%
|
2.86
+20.11%
|
2.38
|
| Diluted NI Availto Com Stockholders |
|
-7.19
-16.46%
|
-6.17
+26.32%
|
-8.37
+52.28%
|
-17.55
|
| Line Item | Trend | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|---|
| Total Assets |
|
13.53
+254.76%
|
3.81
-57.10%
|
8.89
-23.20%
|
11.58
|
| Current Assets |
|
11.51
+587.08%
|
1.68
-73.97%
|
6.44
-29.20%
|
9.09
|
| Cash Cash Equivalents And Short Term Investments |
|
10.79
+940.39%
|
1.04
-80.65%
|
5.36
-24.39%
|
7.09
|
| Cash And Cash Equivalents |
|
10.79
+940.39%
|
1.04
-80.65%
|
5.36
-24.39%
|
7.09
|
| Receivables |
|
0.64
+137.30%
|
0.27
-56.76%
|
0.63
-50.09%
|
1.26
|
| Accounts Receivable |
|
0.64
+137.30%
|
0.27
-56.76%
|
0.63
-50.09%
|
1.26
|
| Prepaid Assets |
|
—
|
—
|
—
|
0.75
|
| Other Current Assets |
|
0.08
-78.81%
|
0.37
-18.16%
|
0.45
-39.79%
|
0.75
|
| Total Non Current Assets |
|
2.02
-5.65%
|
2.14
-12.85%
|
2.45
-1.22%
|
2.48
|
| Net PPE |
|
0.00
-100.00%
|
0.02
-81.65%
|
0.10
+221.18%
|
0.03
|
| Gross PPE |
|
0.00
-100.00%
|
0.02
-87.24%
|
0.14
+103.63%
|
0.07
|
| Accumulated Depreciation |
|
—
|
-0.05
-19.85%
|
-0.04
-10.95%
|
-0.04
|
| Properties |
|
—
|
—
|
—
|
0.00
|
| Buildings And Improvements |
|
—
|
—
|
—
|
0.02
|
| Machinery Furniture Equipment |
|
—
|
0.05
+0.00%
|
0.05
+0.64%
|
0.05
|
| Other Properties |
|
—
|
0.02
-79.91%
|
0.09
+394.84%
|
0.02
|
| Goodwill And Other Intangible Assets |
|
1.98
-4.87%
|
2.08
-4.64%
|
2.18
-4.44%
|
2.28
|
| Other Intangible Assets |
|
1.98
-4.87%
|
2.08
-4.64%
|
2.18
-4.44%
|
2.28
|
| Non Current Prepaid Assets |
|
0.04
-2.88%
|
0.04
-76.28%
|
0.17
+1.18%
|
0.17
|
| Total Liabilities Net Minority Interest |
|
1.08
-41.15%
|
1.83
-0.48%
|
1.84
-15.69%
|
2.18
|
| Current Liabilities |
|
1.08
-41.15%
|
1.83
+0.60%
|
1.82
-14.90%
|
2.14
|
| Payables And Accrued Expenses |
|
1.08
-40.51%
|
1.81
+3.77%
|
1.75
-17.66%
|
2.12
|
| Current Debt And Capital Lease Obligation |
|
—
|
0.02
-73.41%
|
0.07
+293.75%
|
0.02
|
| Current Capital Lease Obligation |
|
0.00
-100.00%
|
0.02
-73.41%
|
0.07
+293.75%
|
0.02
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
0.00
-100.00%
|
0.02
-54.71%
|
0.04
|
| Long Term Debt And Capital Lease Obligation |
|
—
|
0.00
-100.00%
|
0.02
|
0.00
|
| Long Term Capital Lease Obligation |
|
—
|
0.00
-100.00%
|
0.02
|
0.00
|
| Tradeand Other Payables Non Current |
|
—
|
—
|
0.00
-100.00%
|
0.04
|
| Preferred Securities Outside Stock Equity |
|
—
|
—
|
—
|
—
|
| Stockholders Equity |
|
12.45
+528.52%
|
1.98
-71.89%
|
7.05
-24.94%
|
9.39
|
| Common Stock Equity |
|
3.19
+61.11%
|
1.98
-71.89%
|
7.05
-24.94%
|
9.39
|
| Capital Stock |
|
63.78
+35.01%
|
47.24
+1.27%
|
46.64
+9.82%
|
42.47
|
| Common Stock |
|
54.52
+15.41%
|
47.24
+1.27%
|
46.64
+9.82%
|
42.47
|
| Preferred Stock |
|
9.26
|
0.00
|
—
|
—
|
| Share Issued |
|
7.14
+119.92%
|
3.25
+5.59%
|
3.08
+29.21%
|
2.38
|
| Ordinary Shares Number |
|
7.14
+119.92%
|
3.25
+5.59%
|
3.08
+29.21%
|
2.38
|
| Additional Paid In Capital |
|
14.75
+8.66%
|
13.58
+4.12%
|
13.04
+16.67%
|
11.18
|
| Retained Earnings |
|
-65.91
-12.50%
|
-58.59
-11.77%
|
-52.42
-19.01%
|
-44.04
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.17
+31.67%
|
-0.24
-13.03%
|
-0.21
-0.49%
|
-0.21
|
| Other Equity Adjustments |
|
-0.17
+31.67%
|
-0.24
-13.03%
|
-0.21
-0.49%
|
-0.21
|
| Total Equity Gross Minority Interest |
|
12.45
+528.52%
|
1.98
-71.89%
|
7.05
-24.94%
|
9.39
|
| Total Capitalization |
|
12.45
+528.52%
|
1.98
-71.89%
|
7.05
-24.94%
|
9.39
|
| Working Capital |
|
10.43
+6737.41%
|
-0.16
-103.41%
|
4.61
-33.61%
|
6.95
|
| Invested Capital |
|
3.19
+61.11%
|
1.98
-71.89%
|
7.05
-24.94%
|
9.39
|
| Total Debt |
|
0.00
-100.00%
|
0.02
-78.97%
|
0.09
+397.96%
|
0.02
|
| Capital Lease Obligations |
|
0.00
-100.00%
|
0.02
-78.97%
|
0.09
+397.96%
|
0.02
|
| Net Tangible Assets |
|
10.47
+10821.65%
|
-0.10
-102.01%
|
4.87
-31.52%
|
7.11
|
| Tangible Book Value |
|
1.21
+1342.78%
|
-0.10
-102.01%
|
4.87
-31.52%
|
7.11
|
| Other Equity Interest |
|
—
|
—
|
—
|
-0.21
|
| Preferred Stock Equity |
|
9.26
|
—
|
—
|
—
|
| Line Item | Trend | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-7.32
-49.73%
|
-4.89
+26.31%
|
-6.64
+45.95%
|
-12.28
|
| Cash Flow From Continuing Operating Activities |
|
-7.32
-49.73%
|
-4.89
+26.31%
|
-6.64
+45.95%
|
-12.28
|
| Net Income From Continuing Operations |
|
-7.19
-16.46%
|
-6.17
+26.32%
|
-8.37
+52.28%
|
-17.55
|
| Depreciation Amortization Depletion |
|
0.12
-35.89%
|
0.19
+1.41%
|
0.18
+55.24%
|
0.12
|
| Depreciation And Amortization |
|
0.12
-35.89%
|
0.19
+1.41%
|
0.18
+55.24%
|
0.12
|
| Other Non Cash Items |
|
—
|
-0.01
|
—
|
—
|
| Stock Based Compensation |
|
0.73
+35.75%
|
0.54
-56.88%
|
1.25
-44.86%
|
2.26
|
| Change In Working Capital |
|
-0.99
-272.60%
|
0.57
+85.41%
|
0.31
-89.35%
|
2.89
|
| Change In Receivables |
|
-0.38
-206.08%
|
0.36
-36.68%
|
0.56
-72.24%
|
2.03
|
| Change In Prepaid Assets |
|
0.11
-45.30%
|
0.20
-34.62%
|
0.30
+1646.41%
|
-0.02
|
| Change In Payables And Accrued Expense |
|
-0.72
-4167.65%
|
0.02
+103.16%
|
-0.56
-163.01%
|
0.88
|
| Investing Cash Flow |
|
—
|
—
|
0.00
+100.00%
|
-0.01
|
| Cash Flow From Continuing Investing Activities |
|
—
|
—
|
0.00
+100.00%
|
-0.01
|
| Net PPE Purchase And Sale |
|
—
|
—
|
0.00
+100.00%
|
-0.01
|
| Purchase Of PPE |
|
—
|
—
|
0.00
+100.00%
|
-0.01
|
| Sale Of PPE |
|
—
|
—
|
—
|
—
|
| Capital Expenditure |
|
—
|
—
|
—
|
-0.01
|
| Net Investment Purchase And Sale |
|
—
|
—
|
—
|
—
|
| Purchase Of Investment |
|
—
|
—
|
—
|
—
|
| Sale Of Investment |
|
—
|
—
|
—
|
—
|
| Net Intangibles Purchase And Sale |
|
—
|
—
|
—
|
—
|
| Purchase Of Intangibles |
|
—
|
—
|
—
|
—
|
| Financing Cash Flow |
|
17.03
+2776.69%
|
0.59
-87.74%
|
4.83
-58.47%
|
11.63
|
| Cash Flow From Continuing Financing Activities |
|
17.03
+2776.69%
|
0.59
-87.74%
|
4.83
-58.47%
|
11.63
|
| Net Issuance Payments Of Debt |
|
0.00
+100.00%
|
-0.03
|
0.00
|
—
|
| Issuance Of Debt |
|
—
|
—
|
—
|
—
|
| Repayment Of Debt |
|
0.00
+100.00%
|
-0.03
|
0.00
|
—
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Long Term Debt Payments |
|
—
|
-0.03
|
0.00
|
—
|
| Net Long Term Debt Issuance |
|
—
|
-0.03
|
0.00
|
—
|
| Short Term Debt Payments |
|
0.00
+100.00%
|
-0.03
|
—
|
—
|
| Net Short Term Debt Issuance |
|
0.00
+100.00%
|
-0.03
|
—
|
—
|
| Net Common Stock Issuance |
|
7.72
+958.10%
|
0.73
-83.21%
|
4.35
-63.66%
|
11.96
|
| Proceeds From Stock Option Exercised |
|
-0.02
|
0.00
-100.00%
|
0.77
|
0.00
|
| Net Other Financing Charges |
|
-0.54
-404.63%
|
-0.11
+62.23%
|
-0.29
+12.99%
|
-0.33
|
| Changes In Cash |
|
9.71
+325.88%
|
-4.30
-137.95%
|
-1.81
-175.64%
|
-0.66
|
| Effect Of Exchange Rate Changes |
|
0.05
+278.42%
|
-0.03
-133.71%
|
0.08
+182.63%
|
-0.09
|
| Beginning Cash Position |
|
1.04
-80.65%
|
5.36
-24.39%
|
7.09
-9.55%
|
7.84
|
| End Cash Position |
|
10.79
+940.39%
|
1.04
-80.65%
|
5.36
-24.39%
|
7.09
|
| Free Cash Flow |
|
-7.32
-49.73%
|
-4.89
+26.31%
|
-6.64
+45.98%
|
-12.28
|
| Common Stock Issuance |
|
7.72
+958.10%
|
0.73
-83.21%
|
4.35
-63.66%
|
11.96
|
| Issuance Of Capital Stock |
|
17.60
+2312.77%
|
0.73
-83.21%
|
4.35
-63.66%
|
11.96
|
| Net Preferred Stock Issuance |
|
9.88
|
0.00
|
—
|
—
|
| Preferred Stock Issuance |
|
9.88
|
0.00
|
—
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-03-11 View
- 42026-03-10 View
- 42026-03-06 View
- 42026-03-05 View
- 42026-03-04 View
- 42026-03-03 View
- 42026-03-02 View
- 42026-03-02 View
- 8-K2026-02-24 View
- 10-Q2026-02-13 View
- 8-K2026-02-13 View
- 42026-02-02 View
- 42026-01-05 View
- 8-K2025-12-12 View
- 10-K2025-12-12 View
- 8-K2025-12-12 View
- 42025-12-02 View
- 42025-11-06 View
- 8-K2025-10-28 View
- 42025-10-03 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|